

11 - References

References

Drug treatment of other psychiatric conditions CHAPTER 9 References

1. Raman SR, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. *Lancet Psychiatry* 2018; 5:824-835.
2. Piper BJ, et al. Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. *PLoS One* 2018; 13:e0206100.
3. NHS Business Services Authority. Medicines used in mental health - England - 2015/16 to 2022/23. 2023; <https://www.nhsbsa.nhs.uk/statistical-collections/medicines-used-mental-health-england/medicines-used-mental-health-england-201516-202223>.
4. DIVA Foundation. DIVA-5: Diagnostic Interview for ADHD in adults (DIVA). 2019 (last accessed December 2023); <https://www.divacenter.eu/DIVA.aspx?id=461>.
5. National Institute for Health and Care Excellence. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD). Medtech Innovation Briefing [MIB318]. 2023; <https://www.nice.org.uk/advice/mib318>.
6. Shaw M, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Med* 2012; 10:99.
7. Boesen K, et al. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev* 2022; 2:CD012857.
8. Cândido RCF, et al. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev* 2021; 1:CD013011.
9. Castells X, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev* 2018; 8:CD007813.
10. Zhang L, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. *JAMA Network Open* 2022; 5:e2243597.
11. Zhang L, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. *JAMA Psychiatry* 2024; 81:178-187.
12. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline [NG87]. 2018 (last updated September 2019, last accessed December 2023); <https://www.nice.org.uk/guidance/NG87>.
13. Viktorin A, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. *Am J Psychiatry* 2017; 174:341-348.
14. Radonjić NV, et al. Nonstimulant medications for attention-deficit/hyperactivity disorder (ADHD) in adults: systematic review and meta-analysis. *CNS Drugs* 2023; 37:381-397.

Drug group Drug Advantages Disadvantages Non- stimulants Atomoxetine (NE reuptake inhibitor) Not Controlled Drugs – less restrictive prescribing regulations Can help when stimulants are not indicated or not tolerated (e.g. tic disorders, active substance use disorders, others) Might be considered by specialists in case of refractory ADHD or as an alternative to stimulants Require weeks to attain full effect Higher risk of interactions (metabolised by CYP2D6) and effect variability due to genotype – might require dose adjustments²⁶ Lower effect size than stimulants Guanfacine (α 2A-adrenoceptor agonist) In many countries off-label (unlicensed) for ADHD in adults Off-label prescribing may restrict opportunities to transfer to primary care. Viloxazine (5HT- and NE-modulating agent) USA only Bupropion (dopamine and NE reuptake inhibitor) Limited evidence base 5HT, 5-hydroxytryptamine; NE, norepinephrine. Table 9.1 (Continued)

802 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 9 15. Bolea-Alamañac B, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2014; 28:179–203. 16. Cortese S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. *Lancet Psychiatry* 2018; 5:727–738. 17. Heikkinen M, et al. Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a Swedish nationwide cohort of 13 965 patients. *JAMA Psychiatry* 2023; 80:31–39. 18. Cunill R, et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. *Psychopharmacology (Berl)* 2016; 233:187–197. 19. Crunelle CL, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. *Eur Addict Res* 2018; 24:43–51. 20. Yu S, et al. Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis. *J Child Adolesc Psychopharmacol* 2023; 33:40–50. 21. Nasser A, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder. *CNS Drugs* 2022; 36:897–915. 22. Verbeeck W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Syst Rev* 2017; 10:CD009504. 23. National Institute for Health and Care Excellence. Controlled drugs: safe use and management. NICE Guideline [NG46]. 2016 (last checked December 2023); <https://www.nice.org.uk/guidance/ng46/chapter/context>. 24. Gallagher CT, et al. Doctor or drug dealer? International legal provisions for the legitimate handling of drugs of abuse. *Drug Sci Policy Law* 2020; 6:2050324519900070. 25. General Medical Council. Controlled drugs and other medicines where additional safeguards are needed. 2021; <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices/controlled-drugs-and-other-medicines-where-additional-safeguards-are-needed>. 26. Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC® guideline for atomoxetine based on CYP2D6 genotype. 2019 (last checked December 2023); <https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/>.

Revision #1

Created 2026-01-04 20:17:27 UTC by Omar Ayman

Updated 2026-01-04 20:17:27 UTC by Omar Ayman